S-1: Calidi Biotherapeutics Files for Resale of 6.9 Million Shares of Common Stock

Calidi Biotherapeutics has filed a registration statement for the resale of 6.9 million shares of its common stock by existing stockholders.

Summary

• Calidi Biotherapeutics has filed a registration statement for the resale of 6,935,579 shares of its common stock by existing stockholders.
• The shares include 2,050,000 shares issuable upon exercise of Series E warrants, 2,050,000 shares issuable upon exercise of Series F warrants, 221,893 shares issued to Ladenburg Thalmann as placement agent, 102,500 shares issued to Ladenburg as placement agent, 1,069,800 shares issuable upon exercise of Series D warrants, 53,490 shares issued to Ladenburg as placement agent, 698,812 shares issued to Dr. Ronald Rigor, 600,000 shares issuable upon exercise of warrants issued to Dr. Ronald Rigor and Jannice Rigor, 5,000 shares issued to Redchip Companies Inc., 70,155 shares issued to Allan Camaisa, and 13,929 shares issued to Audie de Castro.
• The company will not receive any proceeds from the sale of these shares, but will receive the exercise price of the warrants if they are exercised for cash.
• The selling stockholders may sell the shares in a variety of ways and at varying prices.
• The company's common stock is listed on the NYSE American under the symbol CLDI, with a last reported sale price of $1.93 on December 9, 2024.
• The company is an emerging growth company and a smaller reporting company, and has elected to comply with certain reduced public company disclosure requirements.

Sentiment

Score: 4

Explanation: The document highlights the company's need for additional funding and the risks associated with its novel approach to cancer treatment, which is concerning. However, the company has a clear strategy and is actively pursuing clinical development programs.

Positives

• The company has the potential to receive approximately $8.2 million if all warrants are exercised for cash.

Negatives

• The company will not receive any proceeds from the sale of the shares by the selling stockholders.
• The company is an emerging growth company and a smaller reporting company, and has elected to comply with certain reduced public company disclosure requirements.

Risks

• The company is an immuno-oncology company with a limited operating history and has not generated any revenue to date from product sales.
• The company has incurred significant operating losses since its inception and anticipates that it will incur continued losses for the foreseeable future.
• The company has no products approved for commercial sale and has not generated any revenue from product sales.
• The company needs to raise substantial additional funding and may be forced to delay, reduce or eliminate some or all of its product development programs or cease operations altogether if unable to do so.
• The company's engineered allogeneic stem cell product candidates represent a novel approach to cancer treatment that creates significant challenges.
• The company's business is highly dependent on the success of CLD-101 for newly diagnosed HGG, CLD-101 for recurrent HGG, CLD-201 and CLD-400.
• The company's preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of its product candidates.
• The company's product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval, if at all.
• Even if the company receives marketing approval for its current or future product candidates, its current or future product candidates may not achieve broad market acceptance.
• The regulatory approval processes of the FDA and other regulatory authorities are lengthy, time consuming and inherently unpredictable.
• The company does not anticipate paying any cash dividends for the foreseeable future.
• The company's Charter provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between the company and its stockholders.
• The Sponsor, Metric, anchor investors and other investors purchased or received as an inducement to facilitate the Business Combination the Sponsor Shares that were acquired by the Sponsor, Metric or anchor investors at $0.004 per share price which is significantly below the current market price of a share of the company's common stock.
• The company has registered in another registration statement filed with the SEC 23,301,960 shares of its common stock, among other securities, for resale by certain selling securityholders.
• The company has agreed to file a resale registration statement for the shares of common stock issuable upon conversion of the convertible promissory notes issued on March 8, 2024.
• The company's market is thinly traded which may adversely affect the liquidity and price of its securities.
• The price of the company's stock may be volatile, which could result in substantial losses for investors.
• If the company fails to comply with the continued listing standards of the NYSE American, its common stock could be delisted.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through clinical trials and seeks regulatory approval.

Industry Context

The company operates in the competitive immuno-oncology space, developing novel therapies for cancer treatment, including oncolytic virotherapies and stem cell-based platforms.

Comparison to Industry Standards

• The company's approach to cancer treatment using allogeneic stem cells and enveloped vaccinia virus is novel and differs from many existing therapies.
• The company faces competition from major pharmaceutical and biotechnology companies, as well as smaller companies developing similar or different approaches to cancer treatment.
• The company's success will depend on the efficacy, safety, convenience, and price of its product candidates, as well as the availability of reimbursement from government and third-party payors.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Shareholders may experience losses due to the volatility of the company's stock price.
• The company's ability to continue as a going concern is dependent upon its ability to raise additional funding.

Next Steps

• The company intends to continue its research and development efforts, initiate clinical trials, and seek regulatory approval for its product candidates.
• The company may also explore potential collaboration agreements, strategic alliances, and licensing arrangements.

Key Dates

Keywords

Calidi Biotherapeutics, common stock, resale, warrants, immuno-oncology, stem cell therapy, oncolytic virotherapy, cancer treatment, clinical trials, regulatory approval